Physician profile
Jane S Levy
NPI 1528459211
$13,660.11
in general payments reported to CMS, 2019-2025
31 companies · $3,587 in 2025
The $3,587 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $3,252 · 2023: $2,559 · 2024: $3,777 · 2025: $3,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,639 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,638.78 |
| Education | $284.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,986.60 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,201.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,257.40 | 2021-2025 | |
| Genzyme Corporation | $1,006.20 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $785.32 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $487.44 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $474.65 | 2021-2025 | Ilumya |
| Pfizer INC. | $416.47 | 2022-2025 | |
| Leo Pharma INC. | $386.44 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $355.63 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $350.75 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $344.10 | 2022 | |
| Ucb, INC. | $282.51 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $201.48 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $165.91 | 2024-2025 | Nemluvio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $145.31 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.42 | 2022-2025 | Spevigo |
| Organon LLC | $109.32 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $98.75 | 2024-2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $81.88 | 2021-2025 | Valchlor |
| Paratek Pharmaceuticals, INC. | $79.13 | 2023-2024 | Nuzyra |
| Strata Skin Sciences, INC. | $62.08 | 2022-2024 | Xtrac |
| Almirall LLC | $56.27 | 2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.15 | 2024-2025 | Cabtreo |
| Dermavant Sciences, INC. | $32.57 | 2024 | Vtama |
| Sebela Pharmaceuticals INC. | $31.68 | 2022 | |
| Epi Health, LLC | $20.19 | 2022 | |
| Botanix Sb INC | $15.57 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $15.42 | 2025 | Natroba, Spinosad |
| Integra Lifesciences Corporation | $13.54 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Journey Medical Corporation | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.